Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Financials: Revenue, Profit and Cash Flow
Amneal Pharmaceuticals, Inc. Class A Common Stock reported revenue of $3.02B for the fiscal year ended Dec 31, 2025, up 8.0% from the year before. That year, net income was $127.93M with a net margin of 4.2%, operating cash flow was $339.99M and free cash flow was $241.15M. The quarter ended Sep 30, 2026 had revenue of $862.68M and net income of $12.31M.
Revenue and Margins
The operating margin was 13.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.02B, a compound annual rate of 12.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.02B | +8.0% | 36.9% | 13.1% | 4.2% |
| Dec 2024 | $2.79B | +16.7% | 36.5% | 8.9% | -2.6% |
| Dec 2023 | $2.39B | +8.2% | 34.3% | 8.5% | -2.0% |
| Dec 2022 | $2.21B | +5.7% | 35.5% | -4.3% | -11.5% |
| Dec 2021 | $2.09B | +5.1% | 36.7% | 7.3% | 1.0% |
| Dec 2020 | $1.99B | +22.5% | 31.5% | 4.6% | 3.4% |
| Dec 2019 | $1.63B | -2.2% | 21.7% | -15.3% | -37.1% |
| Dec 2018 | $1.66B | +60.9% | 43.1% | -1.2% | -12.1% |
| Dec 2017 | $1.03B | +1.5% | 50.9% | 23.7% | 16.4% |
| Dec 2016 | $1.02B | N/A | 58.7% | 28.0% | 20.6% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 32.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B | $1.03B | $1.02B |
| Cost of revenue | $1.91B | $1.77B | $1.57B | $1.43B | $1.32B | $1.36B | $1.27B | $946.59M | $507.48M | $420.77M |
| Gross profit | $1.11B | $1.02B | $820.57M | $784.71M | $768.97M | $628.39M | $353.00M | $716.40M | $526.18M | $597.46M |
| Research and development | $193.81M | $196.56M | $167.78M | $200.05M | $201.85M | $179.93M | $188.05M | $194.19M | $171.42M | $179.02M |
| Operating income | $394.10M | $249.33M | $204.37M | -$94.93M | $152.72M | $91.16M | -$248.68M | -$19.67M | $245.10M | $284.88M |
| Net income | $127.93M | -$73.88M | -$48.72M | -$254.79M | $20.17M | $68.58M | -$603.57M | -$201.30M | $169.32M | $209.43M |
| EBITDA | $657.67M | $468.87M | $452.11M | $159.31M | $410.30M | $354.28M | $198.07M | $114.20M | $295.44M | $306.12M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $862.68M | $796.20M | $722.52M | $814.32M | $784.51M | $724.51M | $695.42M | $730.52M | $702.47M | $701.78M | $659.19M | $616.98M |
| Gross profit | $334.12M | $334.51M | $320.11M | $297.19M | $273.97M | $286.25M | $255.89M | $262.87M | $269.56M | $249.95M | $238.06M | $189.83M |
| Operating income | $95.42M | $129.77M | $141.77M | $112.03M | $70.34M | $111.37M | $100.35M | $75.79M | $88.81M | $95.47M | -$10.75M | $14.19M |
| Net income | $12.31M | $69.61M | $78.00M | $49.57M | $18.13M | $35.61M | $24.62M | -$20.74M | $11.76M | $16.79M | -$81.68M | -$93.34M |
Balance Sheet
As of Dec 2025, total debt of $2.57B exceeded cash and equivalents by $2.29B. Shareholder equity was negative, at -$70.79M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B | $3.67B | $4.35B | $1.34B | $1.22B |
| Current assets | $1.91B | $1.59B | $1.38B | $1.41B | $1.52B | $1.55B | $1.21B | $1.29B | $771.93M | $726.11M |
| Cash and equivalents | $282.03M | $110.55M | $91.54M | $25.98M | $247.79M | $341.38M | $151.20M | $213.39M | $74.17M | $27.37M |
| Total liabilities | $3.67B | $3.55B | $3.41B | $3.59B | $3.56B | $3.65B | $3.32B | $3.46B | $1.72B | $1.39B |
| Short-term debt | $6.76M | $324.21M | $213.13M | $89.96M | $30.61M | $45.23M | $21.48M | $21.71M | $89.48M | $36.98M |
| Long-term debt | $2.57B | $2.16B | $2.43B | $2.59B | $2.72B | $2.77B | $2.61B | $2.63B | $1.36B | $813.54M |
| Shareholder equity | -$70.79M | -$109.27M | $19.78M | $298.42M | $360.34M | $303.27M | $232.01M | $504.75M | -$385.74M | -$185.29M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.27B | $3.78B | $3.54B | $3.68B | $3.60B | $3.42B | $3.37B | $3.50B | $3.46B | $3.51B | $3.46B | $3.47B |
| Total liabilities | $4.63B | $3.66B | $3.50B | $3.67B | $3.64B | $3.47B | $3.42B | $3.55B | $3.49B | $3.51B | $3.47B | $3.41B |
| Cash and equivalents | $157.40M | $127.64M | $197.66M | $310.87M | $201.25M | $71.54M | $59.19M | $110.55M | $74.01M | $43.77M | $46.52M | $91.54M |
| Shareholder equity | $531.26M | $33.02M | -$45.41M | -$70.79M | -$109.46M | -$112.12M | -$131.67M | -$109.27M | -$93.43M | -$57.47M | -$63.72M | $19.78M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 70.9% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $339.99M | $295.10M | $345.58M | $65.10M | $241.82M | $379.00M | $1.71M | $250.23M | $234.19M | $115.06M |
| Capital expenditures | $98.84M | $60.34M | $46.80M | $48.80M | $50.94M | $61.84M | $47.18M | $83.09M | $94.77M | $122.76M |
| Free cash flow | $241.15M | $234.76M | $298.78M | $16.30M | $190.88M | $317.17M | -$45.48M | $167.14M | $139.42M | -$7.70M |
| Dividends paid | N/A | N/A | N/A | $17.56M | $57.13M | $3.24M | $0 | $182.64M | $376.13M | $201.59M |
| Share repurchases | N/A | N/A | N/A | $1.72M | $0 | $0 | N/A | $11.78M | $0 | $5.00K |
| Investing cash flow | -$112.26M | -$63.00M | -$69.19M | -$174.31M | -$194.18M | -$317.55M | -$19.58M | -$396.38M | -$98.55M | -$124.61M |
| Financing cash flow | -$31.53M | -$211.79M | -$212.57M | -$106.62M | -$138.12M | $131.81M | -$45.83M | $287.68M | -$95.02M | -$19.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98.30M | -$21.24M | -$26.74M | $130.31M | $118.45M | $83.82M | $7.41M | $118.08M | $141.77M | $39.66M | -$4.41M | $135.82M |
| Capital expenditures | $39.58M | $45.59M | $13.86M | $43.17M | $15.05M | $26.50M | $14.12M | $22.46M | $17.11M | $10.70M | $10.06M | $11.79M |
| Free cash flow | $58.72M | -$66.84M | -$40.60M | $87.15M | $103.40M | $57.32M | -$6.71M | $95.61M | $124.66M | $28.95M | -$14.47M | $124.03M |
Frequently Asked Questions About AMRX
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's annual revenue?
Amneal Pharmaceuticals, Inc. Class A Common Stock reported revenue of $3.02B for the fiscal year ended Dec 31, 2025.
How fast is Amneal Pharmaceuticals, Inc. Class A Common Stock's revenue growing?
Revenue was up 8.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.9%.
Is Amneal Pharmaceuticals, Inc. Class A Common Stock profitable?
Yes. Amneal Pharmaceuticals, Inc. Class A Common Stock reported net income of $127.93M for the fiscal year ended Dec 31, 2025, with a net margin of 4.2%.
How much free cash flow does AMRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $339.99M minus capital expenditures of $98.84M produced free cash flow of $241.15M.
How much debt does Amneal Pharmaceuticals, Inc. Class A Common Stock have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $2.57B, short-term debt of $6.76M and cash and equivalents of $282.03M.
AMRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors